BiotechTube
Home/Pipeline/AN3025

AN3025

Not Specified

PreclinicalActive

Key Facts

Indication
Not Specified
Phase
Preclinical
Status
Active
Company
Adlai Nortye

About Adlai Nortye

Adlai Nortye is a clinical-stage biotech focused on developing innovative oncology therapies, with a core strategy of in-licensing and advancing mid-to-late-stage assets into new, high-need indications. Its most advanced candidate, buparlisib (AN2025), is in a pivotal global Phase 3 trial for head and neck squamous cell carcinoma (HNSCC). The company aims to address significant unmet medical needs by modulating the tumor microenvironment and overcoming resistance to standard treatments like anti-PD-1 therapy.

View full company profile

Therapeutic Areas

Oncology

Other Not Specified Drugs

DrugCompanyPhase
FL116Forlong BiotechnologyNot specified
FL117Forlong BiotechnologyNot specified
FL118Forlong BiotechnologyNot specified
FL301Forlong BiotechnologyNot specified
JSKN016AlphaMab OncologyPhase 1
JSKN033AlphaMab OncologyPhase 1
JSKN022AlphaMab OncologyPhase 1
JSKN027AlphaMab OncologyPhase 1
KN019AlphaMab OncologyPhase 1
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
SR2162SIMR (Australia) BiotechIND Approved